

IN THE MATTER OF

*

BEFORE THE

ROSE MARIE BREEN

*

MARYLAND STATE

Respondent

*

BOARD OF PHARMACY

Registration No. T31003

*

Case No. 25-190

* * * * *

ORDER FOR SUMMARY SUSPENSION

The Maryland State Board of Pharmacy (the “Board”) hereby **SUMMARILY SUSPENDS** the registration of **ROSE MARIE BREEN** (the “Respondent”), Registration Number **T31003**, to practice as a pharmacy technician in the State of Maryland. The Board takes such action pursuant to its authority under Md. Code Ann., State Gov’t § 10-226(c) (2021 Repl. Vol. & 2024 Supp.) and Md. Code Regs. (“COMAR”) 10.34.01.12, having concluded that the public health, safety, or welfare imperatively requires emergency action.

INVESTIGATIVE FINDINGS¹

1. At all relevant times, the Respondent was registered to practice as a pharmacy technician in the State of Maryland under registration number T31003. The Respondent’s pharmacy technician registration was initially issued on or about November 14, 2024. The Respondent’s registration is current through November 30, 2025.

¹ The statements regarding the Respondent’s conduct are only intended to provide the Respondent with reasonable notice of the basis for the Board’s action. They are not intended as, and do not necessarily represent, a complete description of the evidence, either documentary or testimonial, to be offered against the Respondent in this matter.

2. At all relevant times, the Respondent was employed by a national pharmacy chain (the “Pharmacy”)² as a pharmacy technician at two of the Pharmacy’s stores in Easton, Maryland (“Store 1” and “Store 2”).

3. In a fax dated December 11, 2024, the Pharmacy notified the Board that the Respondent was caught stealing controlled substances from one of the Pharmacy’s stores in Easton, Maryland, and admitted to stealing controlled substances from the Pharmacy’s other store in Easton, Maryland. The Pharmacy stated that, at the conclusion of the Pharmacy’s internal investigation, it would notify the Board and submit a Drug Enforcement Agency (“DEA”) Report of Theft or Loss of Controlled Substances Form (“DEA Form 106”) if a loss is confirmed.

4. Upon receipt of the Pharmacy’s notification, the Board initiated an investigation of the Respondent under Case Number 25-190. As part of its investigation, the Board obtained and reviewed, *inter alia*, documents from the Pharmacy’s internal investigation including the Respondent’s written admission and the DEA Form 106 completed by the Pharmacy.

Pharmacy Internal Investigation

5. On December 3, 2024, a Pharmacy District Asset Protection Leader notified a Pharmacy Division Diversion Manager that a pharmacy technician at Store 1 witnessed

² For confidentiality and privacy purposes, the names of individuals and facilities involved in this case are not disclosed in this document. The Respondent may obtain the names of all individuals referenced in this document by contacting the administrative prosecutor.

the Respondent consuming Alprazolam tablets and placing additional tablets in her lab coat pocket, and that surveillance camera footage from December 2, 2024 showed the Respondent removing pills from her lab coat pocket and consuming several pills in the back of Store 1.

6. On December 10, 2024, the Pharmacy Division Diversion Manager interviewed the Respondent in the presence of a Pharmacy District Leader. The interview was memorialized in a two-page written statement which the Respondent signed and affirmed as true. In this statement, the Respondent admitted that she stole Ambien (Zolpidem), Soma (Carisoprodol), Xanax (Alprazolam), Diazepam, and Lunesta (Eszopiclone) from Store 2. The Respondent stated that she began stealing from the Pharmacy about two months prior to the interview, and that she stole the medications by taking them from pill bottles. The Respondent claimed that she stole 34 pills from Store 2.

7. At the conclusion of the interview, the Pharmacy placed the Respondent on immediate suspension and called the Easton Police Department, who issued the Respondent a misdemeanor citation.

8. On January 24, 2025, the Pharmacy completed a DEA Form 106 reporting the loss of controlled substances with a purchase value of \$4,910 due to employee theft. The Pharmacy reported that it terminated the Respondent's employment after conducting an internal investigation in which the Respondent admitted to stealing Ambien (Zolpidem), Soma (Carisoprodol), Xanax (Alprazolam), Diazepam, Lunesta (Eszopiclone), and Clonazepam, and other evidence indicated that the Respondent was responsible for

additional medication loss beyond what she admitted to. The Pharmacy listed the following controlled substances as lost / stolen:

	Substance	NDC No.	Dosage	Quantity
1	ALPRAZOLAM	00781107905	1mg tablet	231
2	ZOLPIDEM TARTRATE	13668000805	10mg tablet	363
3	CARISOPRODOL	50742065601	350mg tablet	7
4	AMBIEN / ZOLPIDEM TARTRATE	00024542131	10mg tablet	66
5	CLONAZEPAM	00093321205	1mg tablet	38
6	CLONAZEPAM	43547040710	1mg tablet	30
7	DIAZEPAM	00172392570	2mg tablet	349
8	CARISOPRODOL	16571078101	350mg tablet	114
9	CARISOPRODOL	50228010901	350mg tablet	15
10	ESZOPICLONE	65862096901	3mg tablet	93
11	CLONAZEPAM	72888015305	1mg tablet	2

Criminal Case

9. Based on the conduct described above, the Respondent was criminally charged in case number D-035-CR-24-060156 in the District Court of Maryland for Talbot County on or about December 10, 2024. On January 28, 2025, the Respondent pled guilty to one count of misdemeanor theft and was sentenced to 180 days' incarceration, all suspended, and one year of supervised probation.

CONCLUSIONS OF LAW

Based on the foregoing investigative findings, the Board concludes, as a matter of law, that the public health, safety, or welfare imperatively requires emergency action in

this case, pursuant to Md. Code Ann., State Gov't § 10-226(c)(2) and COMAR 10.34.01.12.

ORDER

Based on the foregoing Investigative Findings and Conclusions of Law, it is this 12th day of June 2025, by a majority of the Board, hereby:

ORDERED that pursuant to the authority vested in the Board by Md. Code Ann., State Gov't § 10-226(c)(2) (2021 Repl. Vol. & 2024 Supp.), Respondent Rose Marie Breen's registration to practice as a pharmacy technician in the State of Maryland, registration number T31003, is **SUMMARILY SUSPENDED**; and it is further

ORDERED that the Respondent is prohibited from practicing as a pharmacy technician in the State of Maryland; and it is further

ORDERED that the Respondent shall immediately return all registrations to the Board; and it is further

ORDERED that the Respondent has the opportunity to appear before the Board for a post-deprivation show cause hearing. A request for a post-deprivation show cause hearing must be in writing and be made **WITHIN THIRTY (30) DAYS**; and it is further

ORDERED that if the Respondent fails to request a post-deprivation show cause hearing in writing in a timely manner, or if the Respondent requests a post-deprivation show cause hearing but fails to appear when scheduled, the Respondent's registration will remain **SUSPENDED**; and it is further

ORDERED that this **ORDER FOR SUMMARY SUSPENSION** is a **PUBLIC DOCUMENT** pursuant to Md. Code Ann., Gen. Prov. §§ 4-101 *et seq.*

6-12-25
Date


Deena Speights-Napata, M.A.
Executive Director
Maryland Board of Pharmacy